The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.

IF 3.4 2区 医学 Q2 CLINICAL NEUROLOGY Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-24 DOI:10.1080/14737175.2024.2355981
Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg
{"title":"The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.","authors":"Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg","doi":"10.1080/14737175.2024.2355981","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.</p><p><strong>Areas covered: </strong>In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials. The authors also compare the patch to the only other transdermal cholinesterase inhibitor on the market, rivastigmine, and highlight the potential advantages and disadvantages between these two treatments.</p><p><strong>Expert opinion: </strong>While the patch is bio-equivalent, it is rather large and may not be affordable for some patients. In addition, there is no high dose (e.g. 23 mg) equivalent. Nevertheless, transdermal donepezil will be useful for people with AD and their caregivers, given its effectiveness and potential convenience.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"24 6","pages":"607-614"},"PeriodicalIF":3.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2024.2355981","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.

Areas covered: In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials. The authors also compare the patch to the only other transdermal cholinesterase inhibitor on the market, rivastigmine, and highlight the potential advantages and disadvantages between these two treatments.

Expert opinion: While the patch is bio-equivalent, it is rather large and may not be affordable for some patients. In addition, there is no high dose (e.g. 23 mg) equivalent. Nevertheless, transdermal donepezil will be useful for people with AD and their caregivers, given its effectiveness and potential convenience.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于治疗轻度、中度或重度阿尔茨海默病患者的多奈哌齐透皮系统:评论性综述。
简介:胆碱酯酶抑制剂和美金刚是AD(阿尔茨海默病)对症治疗的主要药物;然而,这些药物通常都是口服给药,这对AD患者及其护理人员来说可能很困难:在这篇药物简介和叙述性综述中,作者追溯了经 FDA 批准的新透皮多奈哌齐的发展历程。作者讨论了显示其与口服制剂生物等效性的研究,包括两项双盲安慰剂对照非劣效性试验。作者还将该贴剂与市场上唯一一种透皮胆碱酯酶抑制剂利伐斯的明进行了比较,并强调了这两种治疗方法之间潜在的优缺点:专家意见:虽然这种贴片具有生物等效性,但其体积较大,一些患者可能负担不起。此外,也没有高剂量(如 23 毫克)的同等药物。尽管如此,鉴于其有效性和潜在的便利性,透皮多奈哌齐对注意力缺失症患者及其护理人员还是很有用的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Neurotherapeutics
Expert Review of Neurotherapeutics Medicine-Neurology (clinical)
CiteScore
7.00
自引率
2.30%
发文量
61
审稿时长
4-8 weeks
期刊介绍: Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points
期刊最新文献
The value of hypothermia as a neuroprotective and antiepileptic strategy in patients with status epilepticus: an update of the literature. UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder. The major challenges with pharmacologic management of chronic traumatic encephalopathy. Relationship between anti-seizure medication and behaviors that challenge in older persons with intellectual disability and epilepsy: a review. Can pharmacotherapy help to reduce trichotillomania?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1